Anti-Hepatitis C Virus antibody

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Hepatitis C Virus (HCV) is an RNA virus that causes liver infection. It has a small and compact genome of approximately 9.6 kilobases. Structurally HCV contains a single-stranded RNA encased in a nucleocapsid. This virus produces structural proteins like Core E1 and E2 and non-structural proteins such as NS3 NS4A NS4B NS5A and NS5B. These non-structural proteins play key roles in viral replication and assembly. Expression of HCV predominantly occurs in liver hepatocytes where the virus hijacks the host cellular machinery to replicate.

Biological function summary

Hepatitis C virus engages with host cell pathways to maintain its lifecycle. HCV forms replication complexes within host cells that are critical for its genome replication. These complexes actively interact with lipid metabolism processes which is why the virus associates closely with lipid droplets within hepatocytes. Through this interaction HCV affects host lipid homeostasis a component necessary for viral assembly and release. Since it forms structures that modify the host cell ER membrane understanding the HCV interaction with host cells is fundamental for therapeutic targeting.

Pathways

HCV has significant interactions with the innate immune response and lipid metabolism pathways. The virus disrupts interferon signaling by degrading proteins like IRF3 and blocking STAT1 phosphorylation undermining host antiviral defenses. Additionally HCV interplays with the PI3K-Akt-mTOR pathway important for host cell survival leveraging proteins such as Akt for its benefit. NS5A protein is known to modulate these pathways therefore influencing both the infection state and treatment strategies.

Chronic infection with HCV can lead to severe conditions like liver cirrhosis and hepatocellular carcinoma. The virus promotes hepatic fibrosis through continuous inflammation and liver cell damage. Additionally individuals with hepatitis C are at increased risk for developing metabolic disorders such as insulin resistance. Viral proteins like Core and NS5A drive these adverse outcomes by interacting with cell processes altering insulin signaling pathways and contributing to oncogenic transformations. Understanding these interactions is essential for developing effective HCV antibodies and therapeutic agents.